Bernstam et al presented findings from an expansion cohort of a phase 1 trial testing the bispecific HER2-targeted antibody zanidatamab in patients with HER2-overexpressing biliary tract cancer.
Outcomes of lenvatinib-receiving patients who progressed to Child-Pugh B liver function within the first 8 weeks of treatment were compared with those of patients who maintained Child-Pugh A classification during the same time period.
Investigators present findings from a phase 1a study evaluating the safety and efficacy of MIV-818 in patients with hepatocellular carcinoma (HCC), hepatic cholangiocarcinoma (CCA), or liver metastases from solid tumors.
The phase 1b/2 PLANET study tested the combination of lanreotide and pembrolizumab in advanced well- or moderately differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Kasi et al compared a novel, artificial intelligence (AI)-based cancer clinical trial search tool with ClinicalTrials.gov to determine which afforded a better user experience.
A cross-sectional survey assessed health-related quality of life in colorectal cancer survivors (≤50 years).
Investigators of the phase 1b/2 PANTHERA trial presented updated clinical and molecular profiling data from 43 patients who received frontline pembrolizumab, trastuzumab, and chemotherapy.
Continued follow-up showed nivolumab conferred benefit regardless of best overall response.
ATTRACTION-1 investigators report the final findings from the study, derived from a minimum follow-up of 5 years.
This post hoc analysis of KEYNOTE-240 was performed to determine whether objective response at landmark is prognostic of longer survival after landmark time.
Please login or register first to view this content.
